Vitamin K2 Supplement Guide: MK-7 Benefits, Dosage, and Clinical Evidence (2026)

What Is Vitamin K2 and How Does It Differ from K1?

Vitamin K2 (menaquinone) is a fat-soluble vitamin responsible for activating proteins that regulate where calcium goes in your body. While vitamin K1 (phylloquinone) primarily supports blood clotting in the liver, K2 works in bones, arteries, and other tissues to ensure calcium is deposited where it belongs and kept out of where it causes harm.

The vitamin K family includes two main forms: K1 and K2. Vitamin K1 is abundant in green leafy vegetables, spinach, kale, and broccoli all contain substantial amounts. Your liver uses K1 preferentially for producing clotting factors. Vitamin K2, by contrast, is found primarily in fermented foods and animal products, and its role extends far beyond coagulation.

K2 exists as a series of subtypes designated MK-4 through MK-13, where the number indicates the length of the isoprenoid side chain. Two forms dominate the supplement market: MK-4 (menaquinone-4) and MK-7 (menaquinone-7). These are not interchangeable, they have fundamentally different pharmacokinetics, which affects dosing, timing, and clinical outcomes.

The biological mechanism centers on a process called gamma-carboxylation. K2 serves as a cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), which activates vitamin K-dependent proteins (VKDPs) by adding carboxyl groups to specific glutamic acid residues. Without adequate K2, these proteins remain in their undercarboxylated, and largely inactive — forms (Jadhav et al., 2022).

Two VKDPs are particularly relevant to supplementation:

Osteocalcin (OC), produced by osteoblasts, this protein binds calcium and incorporates it into the bone mineral matrix. Undercarboxylated osteocalcin (ucOC) cannot bind calcium effectively, meaning your bones miss out on available calcium even if your dietary intake is adequate.

Matrix Gla Protein (MGP), synthesized by vascular smooth muscle cells, MGP is the most potent endogenous inhibitor of arterial calcification. Without K2-dependent carboxylation, MGP cannot prevent calcium from depositing in arterial walls. Blood tests for uncarboxylated MGP have been studied as markers of vascular vitamin K status and of cardiovascular calcification risk (Schurgers et al., 2008).

This dual role, bone mineralization and arterial protection, is what researchers call the "calcium paradox": the same element that strengthens your skeleton can stiffen your arteries, and vitamin K2 is a critical determinant of which direction the balance tips.

MK-4 vs. MK-7: Which Form Should You Choose?

MK-7 is the more practical form for most people. It stays in the blood much longer than other vitamin K forms, so a single daily microgram dose keeps levels steady and improves osteocalcin carboxylation (Schurgers et al., 2007). MK-4 clears quickly and is used in Japan at a pharmacological dose of 45 mg/day (Sato et al., 2020).

The pharmacokinetic gap between the two is large. MK-4 leaves the blood quickly, which is why Japanese osteoporosis protocols use 45 mg/day (45,000 µg) divided across the day (Sato et al., 2020).

MK-7, produced when soybeans are fermented with Bacillus subtilis to make natto, behaves differently. In a head-to-head study in healthy volunteers, K1 and MK-7 both peaked about 4 hours after intake, but MK-7 had a much longer half-life, built up to 7 to 8 times higher blood levels with daily use, and carboxylated osteocalcin more completely (Schurgers et al., 2007).

Most of the randomized outcome data also involve MK-7. The VitaK-CAC coronary trial used 360 µg/day (Vossen et al., 2026), and the three-year bone and arterial stiffness trials in postmenopausal women used 180 µg/day (Knapen et al., 2013).

MK-4 does have a unique property: it is the form found naturally in human tissues, and MK-7 is partially converted to MK-4 after absorption. Some researchers argue that MK-4 has tissue-specific gene regulatory effects beyond GGCX-dependent carboxylation. However, achieving therapeutic MK-4 tissue levels through supplementation requires the high milligram doses that are impractical for routine daily use.

For most supplement consumers, MK-7 offers the clearest evidence base, the most convenient dosing, and the strongest clinical data. MK-4 at pharmacological doses (45 mg/day) remains an option for specific clinical contexts, particularly in Japan where it is prescribed for osteoporosis, but it is not the practical choice for daily health maintenance.

Vitamin K2 and Bone Health: What the Clinical Trials Show

In the largest positive trial, 244 healthy postmenopausal women took 180 µg/day of MK-7 or placebo for three years. MK-7 slowed the age-related loss of bone mineral content and density at the lumbar spine and femoral neck, though not at the total hip, and improved bone strength indices (Knapen et al., 2013). A three-year trial in women with osteopenia found no bone density benefit at 375 µg/day (Rønn et al., 2021), so the evidence is mixed.

The relationship between vitamin K2 and bone health centers on osteocalcin, the most abundant non-collagenous protein in bone. When vitamin K2 carboxylates osteocalcin, the protein gains the ability to bind calcium ions and hydroxyapatite crystals, the mineral component of bone matrix. Without carboxylation, osteocalcin floats through the bloodstream as ucOC, unable to contribute to bone mineralization.

The Knapen trial randomized 244 healthy postmenopausal women to 180 µg/day of MK-7 or placebo for three years. MK-7 improved vitamin K status, reduced the decline in bone mineral content and density at the lumbar spine and femoral neck, improved femoral neck strength indices, and reduced loss of vertebral height in the lower thoracic spine (Knapen et al., 2013).

A 2024 meta-analysis of randomized trials in middle-aged and older adults found that vitamin K supplementation raised lumbar spine BMD, increased carboxylated osteocalcin and lowered uncarboxylated osteocalcin, with the clearest effects in women; vitamin K2 accounted for most of the benefit (Xie et al., 2024). A 2025 meta-analysis limited to postmenopausal osteoporosis agreed that K2 improves osteocalcin markers but said longer trials are still needed to show bone density gains (Zhang et al., 2025).

The bone data are not one-sided. In a three-year trial of 142 postmenopausal women with osteopenia, all of whom also took calcium and vitamin D3, 375 µg/day of MK-7 lowered undercarboxylated osteocalcin, yet bone density fell at every site with no difference from placebo (Rønn et al., 2021). The contrast with the Knapen result may reflect the population, the background calcium and vitamin D, or chance.

The practical takeaway from the bone evidence: MK-7 supplementation at 180 µg/day appears to slow age-related bone loss when used consistently for at least one year, with the strongest evidence in healthy postmenopausal women before significant bone disease develops. It is not a substitute for first-line osteoporosis pharmacotherapy in diagnosed cases.

Vitamin K2 and Heart Health: The Calcium Paradox Explained

In the 2026 VitaK-CAC trial, adults with symptomatic coronary artery disease took 360 µg/day of MK-7 or placebo for two years. Median coronary calcium scores rose from 145 to 214 Agatston units with placebo and from 135 to 184 with MK-7, a significant difference (P = .02), with a similar result for calcium mass (Vossen et al., 2026). The authors said the meaning for plaque stability and heart events is still unknown.

Coronary artery calcification (CAC) is a hallmark of atherosclerotic plaque progression and a strong independent predictor of cardiovascular events. CAC scores, measured by CT imaging using the Agatston method, provide a quantitative measure of calcified plaque burden. Higher scores correlate directly with higher risk of heart attack and cardiovascular death.

The biological logic for K2 in cardiovascular protection is straightforward: matrix Gla protein (MGP), once activated by K2-dependent carboxylation, binds calcium crystals in the arterial wall and prevents their growth. When K2 is insufficient, MGP remains undercarboxylated and unable to perform this protective function. Population studies consistently show that higher dietary K2 intake — but not K1, associates with reduced cardiovascular mortality.

The Rotterdam Study followed 4,807 Dutch adults without a prior heart attack from 1990–1993 to 2000. Compared with the lowest third of dietary menaquinone (K2) intake, the highest third had 57% lower coronary heart disease mortality, 26% lower all-cause mortality and about half the odds of severe aortic calcification. Phylloquinone (K1) intake was not related to any of these outcomes (Geleijnse et al., 2004).

A separate Dutch cross-sectional study of 564 postmenopausal women found that higher menaquinone intake was associated with less coronary calcification (relative risk 0.80), while phylloquinone intake was not (Beulens et al., 2009).

Randomized data on arteries exist too. In 244 healthy postmenopausal women, 180 µg/day of MK-7 for three years improved arterial stiffness, especially in women who started with stiffer arteries, and cut dp-ucMGP by 50% compared with placebo (Knapen et al., 2015).

The observational data needed a randomized test, and VitaK-CAC supplied one. Patients with symptomatic coronary disease and calcium scores of 50 to 400 Agatston units took 360 µg/day of MK-7 or placebo for two years. Plasma MK-7 rose from a median of 0.50 to 6.56 µg/L in the MK-7 group. Calcium scores climbed in both groups, but less with MK-7 (from 135 to 184 vs. 145 to 214 AU; P = .02), and the rise tracked the number of noncalcified plaques that became partly calcified (Vossen et al., 2026).

The investigators framed the result cautiously. No significant adverse effects were seen, but they concluded that the effect on plaque stability, and therefore on heart attack risk, remains to be determined (Vossen et al., 2026).

Vitamin K2 and Vitamin D3: Why They Work Together

Vitamin D3 increases intestinal calcium absorption but does not control where that calcium ends up. Vitamin K2 activates the proteins that direct absorbed calcium into bones and away from arteries. Taking D3 without adequate K2 may increase calcium levels in the bloodstream without the guidance system to deposit it properly, a mechanistic basis for combining the two.

The D3-K2 partnership is one of the most physiologically coherent supplement combinations available. Here is the sequential logic:

Vitamin D3, once converted to its active form (1,25-dihydroxyvitamin D or calcitriol), upregulates the expression of both osteocalcin in bone and MGP in arterial smooth muscle cells. This means D3 increases the production of the very proteins that need K2-dependent carboxylation to function. Without K2, D3-stimulated osteocalcin and MGP are produced in abundance but remain inactive — you get more protein but not more functional protein.

Outcome data on the pairing are thinner than the mechanism suggests. In the Rønn trial, everyone took calcium and vitamin D3, and adding MK-7 did not change bone density over three years (Rønn et al., 2021). A 2025 substudy of a two-year trial found that high-dose K2 plus D3 lowered dp-ucMGP but did not change epicardial fat or markers of systemic inflammation (Hasific et al., 2025). The case for combining them rests mainly on physiology rather than on head-to-head trials.

Practical dosing: most evidence-based protocols pair 1,000–5,000 IU of vitamin D3 with 100–200 µg of MK-7. Both are fat-soluble and absorb best with a meal containing dietary fat.

How Much Vitamin K2 Should You Take?

The evidence-based range for MK-7 is 100–360 µg/day. For general bone and cardiovascular maintenance, 100–200 µg/day is the standard starting dose. For individuals with documented coronary artery calcification or those taking high-dose vitamin D3, 200–360 µg/day aligns with the dosing used in the VitaK-CAC trial. MK-7 should be taken with a fat-containing meal for optimal absorption (Knapen et al., 2013) (Vossen et al., 2026).

There is no official Recommended Dietary Allowance (RDA) specifically for vitamin K2. The current Adequate Intake (AI) for total vitamin K is 90 µg/day for women and 120 µg/day for men, but this was set based on K1 and clotting function, not K2 and extrahepatic carboxylation.

The clinical trial evidence supports the following MK-7 doses:

180 µg/day, the dose used in the three-year postmenopausal bone health trial. This is the most widely validated dose for bone-related outcomes and represents a solid maintenance level (Knapen et al., 2013).

360 µg/day, the dose used in the VitaK-CAC cardiovascular trial. This higher dose is appropriate for targeted cardiovascular protection, particularly in individuals with existing CAC or high cardiovascular risk (Vossen et al., 2026).

100 µg/day, a common label dose. Even modest daily MK-7 intake is biologically active: in Schurgers' study, 50 µg/day or more was enough to potentially interfere with warfarin control (Schurgers et al., 2007).

Timing matters: take MK-7 with your largest meal of the day that contains dietary fat (olive oil, avocado, nuts, eggs, or fatty fish). Fat-soluble vitamins require bile acid emulsification for absorption, and taking K2 on an empty stomach dramatically reduces bioavailability.

One practical note: if you take both vitamin D3 and K2, they can share the same fat-containing meal. Many supplement brands now combine D3 and K2 in a single capsule, which simplifies the protocol.

Food Sources of Vitamin K2

Natto, made from fermented soybeans, is the richest natural source of MK-7, and a 2025 meta-analysis found that habitual natto intake raises serum MK-7 and improves osteocalcin carboxylation (Wen et al., 2025). Aged cheeses, egg yolks and dark poultry meat supply smaller amounts of other menaquinones. Most Western diets contain little K2 because the richest sources are fermented foods many people rarely eat.

Unlike vitamin K1, which is abundant in readily available vegetables, vitamin K2 is concentrated in foods that require fermentation or come from specific animal sources:

Natto, Japanese fermented soybeans, is the richest natural source of MK-7 (Wen et al., 2025). Its taste and sticky texture put many people off outside Japan, which limits it as a practical K2 strategy.

Hard and aged cheeses, such as Gouda and Emmental, contain longer-chain menaquinones made by the bacteria used in fermentation; aged varieties generally contain more than fresh cheeses.

Egg yolks contain small amounts of MK-4.

Dark chicken meat and liver also provide MK-4 in small amounts.

Sauerkraut and other fermented vegetables, contain K2 depending on the bacterial strains involved, but generally at much lower levels than natto or cheese.

The challenge for most Western diets is clear: unless you eat natto regularly or consume significant amounts of aged cheese, dietary K2 intake is likely below the levels shown to produce clinical benefits in trials. This is why supplementation is often the practical route to adequate K2 status, particularly for people supplementing with vitamin D3, where the need for K2-dependent carboxylation is amplified.

Vitamin K2 Side Effects and Safety

Vitamin K2 was well tolerated in trials: the two-year VitaK-CAC study reported no significant adverse effects at 360 µg/day (Vossen et al., 2026). The key exception is warfarin and other vitamin K antagonists. MK-7 accumulates with daily use, and intakes of 50 µg/day or more may interfere with oral anticoagulant control (Schurgers et al., 2007).

Vitamin K2 at standard supplemental doses (100–360 µg/day) is well-tolerated in clinical trials, with no significant adverse events reported in multi-year studies. The Food and Nutrition Board has not established an Upper Tolerable Intake Level (UL) for any form of vitamin K, noting a lack of evidence for toxicity even at high doses.

The critical exception involves anticoagulant medications:

Warfarin (Coumadin) and other vitamin K antagonists, these drugs work by blocking the vitamin K cycle that activates clotting factors. Any supplemental vitamin K, including K2, can partially reverse this blockade and reduce anticoagulant effectiveness. Patients on warfarin should not take vitamin K2 supplements without explicit medical supervision and INR monitoring. This is not a minor caution — it is a clinically significant drug interaction that can increase thrombotic risk.

Direct oral anticoagulants (DOACs), medications like apixaban, rivaroxaban, and dabigatran work through different mechanisms than warfarin and are not affected by vitamin K intake. People on DOACs generally can take K2 supplements, but should still inform their prescribing physician.

Outside of vitamin K antagonists, no clinically important drug interactions have been established for K2 at supplement doses.

People with a history of blood clots or those taking antiplatelet medications (aspirin, clopidogrel) should discuss K2 supplementation with their healthcare provider. While K2 supports normal clotting function rather than promoting excessive clotting, medical guidance is appropriate for anyone with a clotting history.

Who Should Consider Vitamin K2 Supplementation?

The strongest evidence supports K2 supplementation for postmenopausal women at risk of bone loss, anyone taking vitamin D3 supplements (especially at doses above 2,000 IU/day), and individuals with documented coronary artery calcification. People on a Western diet low in fermented foods are also likely to benefit from K2, given the difficulty of achieving clinically relevant intake through diet alone.

Based on the current clinical evidence, the following populations have the clearest rationale for K2 supplementation:

Postmenopausal women, the most direct evidence for bone protection comes from this group. Three-year RCT data shows that MK-7 at 180 µg/day slows bone loss at clinically relevant sites. Supplementation is particularly logical if combined with vitamin D3 and calcium as part of a broader bone health strategy (Knapen et al., 2013).

Vitamin D3 supplementers, if you take vitamin D3, you are increasing calcium absorption. Adding K2 ensures that the calcium-regulating proteins stimulated by D3 are properly carboxylated and functional. This is the D3-K2 synergy described above.

Individuals with cardiovascular risk, people with documented coronary artery calcification, metabolic syndrome, type 2 diabetes, or chronic kidney disease face accelerated vascular calcification. The VitaK-CAC trial provides the first RCT evidence supporting K2 supplementation in patients with existing CAD (Vossen et al., 2026).

Adults with low dietary K2 intake, if your diet is low in natto, aged cheese, egg yolks, and organ meats, functional K2 deficiency is likely. Elevated dp-ucMGP levels (a blood test available through some labs) can indicate low vascular vitamin K status.

People over 50. K2 status tends to decline with age while the need for extrahepatic carboxylation increases due to rising cardiovascular and bone health risks.

Who should NOT supplement K2 without medical guidance: anyone taking warfarin or other vitamin K antagonist anticoagulants. This is non-negotiable, the interaction is well-established and clinically dangerous.

Is vitamin K2 safe to take every day?

Yes. Clinical trials have used MK-7 at 180–360 µg/day for two to three years with excellent safety profiles. No upper tolerable intake level has been set for vitamin K2 due to the absence of toxicity evidence at supplemental doses. The one exception is for people taking warfarin or other vitamin K antagonist blood thinners, who must avoid K2 supplements without medical supervision.

Does vitamin K2 remove calcium from arteries?

Current evidence points to slowing, not reversal. In VitaK-CAC, coronary calcium scores rose in both groups over two years, just less with MK-7 (a median rise of 49 vs. 69 Agatston units) (Vossen et al., 2026). Whether longer use can halt or reverse calcification has not been tested.

Can you take vitamin K2 with vitamin D3?

Yes. Vitamin D3 increases calcium absorption and the production of osteocalcin and MGP, and K2 activates those proteins, so the pairing makes physiological sense. Trial support for the combination is limited, though: adding MK-7 to calcium and D3 did not change bone density in women with osteopenia (Rønn et al., 2021). A common pairing is 1,000 to 2,000 IU of D3 with 100 to 200 µg of MK-7, taken with a meal that contains some fat.

How long does it take for vitamin K2 to work?

Blood markers of vitamin K status change within weeks of starting MK-7. Clinical outcomes take much longer: the bone trial ran three years (Knapen et al., 2013) and the coronary trial two years (Vossen et al., 2026). K2 is a long-term supplement, not a quick fix.

What is the best form of vitamin K2 supplement?

MK-7 has the most clinical data. It has a long half-life, works at microgram doses, and is the form used in the bone, arterial stiffness and coronary calcium trials. Look for labels that say MK-7 or menaquinone-7 rather than just vitamin K2.

Does vitamin K2 have any side effects?

Trials at 180 to 360 µg/day have not reported meaningful side effects (Vossen et al., 2026). The main risk is the interaction with warfarin and other vitamin K antagonists (Schurgers et al., 2007).